Form 8-K - Current report:
SEC Accession No. 0001420720-23-000014
Filing Date
2023-02-16
Accepted
2023-02-16 17:02:57
Documents
13
Period of Report
2023-02-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20230210x8k.htm   iXBRL 8-K 34269
  Complete submission text file 0001420720-23-000014.txt   143564

Data Files

Seq Description Document Type Size
2 EX-101.SCH ibio-20230210.xsd EX-101.SCH 4009
3 EX-101.DEF ibio-20230210_def.xml EX-101.DEF 3279
4 EX-101.LAB ibio-20230210_lab.xml EX-101.LAB 11412
5 EX-101.PRE ibio-20230210_pre.xml EX-101.PRE 8543
7 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20230210x8k_htm.xml XML 3867
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

IRS No.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 23639253
SIC: 2834 Pharmaceutical Preparations